心血管药物基因组学。
Cardiovascular pharmacogenomics.
机构信息
Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-0575, USA.
出版信息
Circ Res. 2011 Sep 16;109(7):807-20. doi: 10.1161/CIRCRESAHA.110.230995.
Abstract
Patients vary in their responses to drug therapy, and some of that variability is genetically determined. This review outlines general approaches used to identify genetic variation that influences drug response. Examples from specific therapeutic areas are presented, such as cholesterol management, arrhythmias, heart failure, hypertension, warfarin anticoagulation, and antiplatelet agents. A brief view of potential pathways to implementation is presented.
摘要
患者对药物治疗的反应存在差异，其中一些差异是由遗传决定的。本综述概述了用于识别影响药物反应的遗传变异的一般方法。还呈现了来自特定治疗领域的例子，如胆固醇管理、心律失常、心力衰竭、高血压、华法林抗凝和抗血小板药物。还简要介绍了潜在的实施途径。
相似文献
1
Cardiovascular pharmacogenomics.心血管药物基因组学。
Circ Res. 2011 Sep 16;109(7):807-20. doi: 10.1161/CIRCRESAHA.110.230995.
2
Cardiovascular drugs and the genetic response.心血管药物与基因反应。
Methodist Debakey Cardiovasc J. 2014 Jan-Mar;10(1):13-7. doi: 10.14797/mdcj-10-1-13.
3
Pharmacogenetics and cardiovascular disease--implications for personalized medicine.药物遗传学与心血管疾病——对个性化医学的启示。
Pharmacol Rev. 2013 May 17;65(3):987-1009. doi: 10.1124/pr.112.007252. Print 2013 Jul.
4
Cardiovascular pharmacogenomics and individualized drug therapy.心血管药物基因组学与个体化药物治疗
Nat Rev Cardiol. 2009 Oct;6(10):632-8. doi: 10.1038/nrcardio.2009.154. Epub 2009 Aug 25.
5
Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.心血管药物基因组学的机遇与挑战：从发现到实施。
Circ Res. 2018 Apr 27;122(9):1176-1190. doi: 10.1161/CIRCRESAHA.117.310965.
6
Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner.临床医生的心血管药物动力学、药效学和药物基因组学
J Cardiovasc Pharmacol Ther. 2016 Jan;21(1):20-6. doi: 10.1177/1074248415590196. Epub 2015 Jun 8.
7
Pharmacogenomics: the genetics of variable drug responses.药物基因组学：药物反应变异性的遗传学
Circulation. 2011 Apr 19;123(15):1661-70. doi: 10.1161/CIRCULATIONAHA.109.914820.
8
Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.心血管疾病中的药物基因组学挑战：药物实例及未来整合至临床实践的考量
Curr Pharm Biotechnol. 2017;18(3):231-241. doi: 10.2174/1389201018666170123153626.
9
Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.心力衰竭的药物遗传学：心血管药物基因组学的证据、机遇和挑战。
J Cardiovasc Transl Res. 2008 Mar;1(1):25-36. doi: 10.1007/s12265-007-9007-8. Epub 2008 Jan 29.
10
Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009.心血管疾病中的药物遗传学：从前景迈向现实的挑战：2009年6月加拿大国际试验网络与中心网络会议（CANNeCTIN）上讨论的概念
Clin Cardiol. 2014 Jan;37(1):48-56. doi: 10.1002/clc.22200. Epub 2013 Sep 17.
引用本文的文献
1
Precision medicine in the management of cardiac arrhythmias.心律失常管理中的精准医学
Herz. 2025 Apr;50(2):88-95. doi: 10.1007/s00059-025-05298-x. Epub 2025 Mar 8.
2
Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review.药物基因组学及其在心血管疾病中的作用：一篇叙述性文献综述。
Curr Cardiol Rev. 2025;21(4):e1573403X334668. doi: 10.2174/011573403X334668241227074314.
3
A Brief Introduction to Management of LQTS.长QT综合征管理简介
Rev Cardiovasc Med. 2022 May 5;23(5):164. doi: 10.31083/j.rcm2305164. eCollection 2022 May.
4
Individualized Dose-Response to Statins Associated with Cardiovascular Disease Outcomes.他汀类药物的个体化剂量反应与心血管疾病结局的关系
JACC Adv. 2024 Apr;3(4). doi: 10.1016/j.jacadv.2024.100894. Epub 2024 Mar 7.
5
Novel Gene Polymorphisms for Stable Warfarin Dose in a Korean Population: Genome-Wide Association Study.韩国人群中与华法林稳定剂量相关的新型基因多态性：全基因组关联研究
Biomedicines. 2023 Aug 19;11(8):2308. doi: 10.3390/biomedicines11082308.
6
Novel molecular mechanisms of doxorubicin cardiotoxicity: latest leading-edge advances and clinical implications.多柔比星心脏毒性的新分子机制：最新前沿进展及其临床意义。
Mol Cell Biochem. 2024 May;479(5):1121-1132. doi: 10.1007/s11010-023-04783-3. Epub 2023 Jun 13.
7
Variants in , and Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease.心血管疾病患者中与对华法林敏感性和反应相关的、和基因的变异
Int J Gen Med. 2021 Mar 25;14:1093-1100. doi: 10.2147/IJGM.S298597. eCollection 2021.
8
Effects of Polymorphisms in Myc-Related Genes on Bleeding Complications in Patients with Stable Warfarin Responses.Myc 相关基因多态性对稳定华法林反应患者出血并发症的影响。
Cardiovasc Ther. 2019 May 8;2019:1813747. doi: 10.1155/2019/1813747. eCollection 2019.
9
Genetic variations in the transcription factors and and bleeding complications in patients receiving warfarin therapy.转录因子中的基因变异与接受华法林治疗患者的出血并发症。
Drug Des Devel Ther. 2019 May 17;13:1717-1727. doi: 10.2147/DDDT.S198018. eCollection 2019.
10
Withdrawal of two generic clopidogrel products in Saudi Arabia for non-bio-equivalence.沙特阿拉伯因非生物等效性撤回两种氯吡格雷仿制药产品。
Ann Saudi Med. 2018 May-Jun;38(3):233-234. doi: 10.5144/0256-4947.2018.233.
本文引用的文献
1
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.台湾的卡马西平诱导的毒性作用和 HLA-B*1502 筛查。
N Engl J Med. 2011 Mar 24;364(12):1126-33. doi: 10.1056/NEJMoa1009717.
2
From expression QTLs to personalized transcriptomics.从表达数量性状基因座到个性化转录组学。
Nat Rev Genet. 2011 Apr;12(4):277-82. doi: 10.1038/nrg2969. Epub 2011 Mar 9.
3
Charting a course for genomic medicine from base pairs to bedside.为基因组医学绘制从碱基对到床边的路线图。
Nature. 2011 Feb 10;470(7333):204-13. doi: 10.1038/nature09764.
4
Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions.儿茶酚胺受体信号转导的心血管药物基因组学：临床意义和未来方向。
Clin Pharmacol Ther. 2011 Mar;89(3):366-78. doi: 10.1038/clpt.2010.315. Epub 2011 Feb 2.
5
The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.缺失的关联：VKORC1 和 CYP2C9 中基于测序的新型 SNP 的发现，这些 SNP 影响非裔美国人的华法林剂量。
Clin Pharmacol Ther. 2011 Mar;89(3):408-15. doi: 10.1038/clpt.2010.322. Epub 2011 Jan 26.
6
The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies.eMERGE 网络：一个由生物库组成的联盟，与电子病历数据相关联，用于进行基因组研究。
BMC Med Genomics. 2011 Jan 26;4:13. doi: 10.1186/1755-8794-4-13.
7
The emerging role of electronic medical records in pharmacogenomics.电子病历在药物基因组学中的新兴作用。
Clin Pharmacol Ther. 2011 Mar;89(3):379-86. doi: 10.1038/clpt.2010.260. Epub 2011 Jan 19.
8
Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study.基质金属蛋白酶 3（MMP3）多态性对与降压治疗相关的卒中风险的遗传药理学效应：与高血压相关治疗的遗传学研究。
Stroke. 2011 Feb;42(2):330-5. doi: 10.1161/STROKEAHA.110.593798. Epub 2010 Dec 23.
9
Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.SLCO1B1 常见非同义突变导致 2 型糖尿病常规治疗患者他汀不耐受：一项 go-DARTS 研究。
Clin Pharmacol Ther. 2011 Feb;89(2):210-6. doi: 10.1038/clpt.2010.255. Epub 2010 Dec 22.
10
Paraoxonase-1 is a major determinant of clopidogrel efficacy.对氧磷酶 1 是氯吡格雷疗效的主要决定因素。
Nat Med. 2011 Jan;17(1):110-6. doi: 10.1038/nm.2281. Epub 2010 Dec 19.
Zotero 插件